Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 3696 · · 10 pages · English
Summary by 6ix AI
It reports on the company's authorized and registered share capital, confirming a total at the end of the month. The document also includes details on movements in issued shares, including an increase in the number of issued ordinary shares during the month. Additionally, it confirms compliance with public float requirements as per exchange rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
InSilico Medicine Cayman TopCo on 6ix
Earlier from InSilico Medicine Cayman TopCo
- Voluntary announcement InSilico Medicine nominates next-generation small molecule GIPR antagonist for potential intervention of obesity and related disorders
- Voluntary announcement InSilico Medicine entered into an AI co-development collaboration with a contract value up to tens of millions of U.S. dollars to build and commercialize foundation models for biology
- Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
- Voluntary announcement increase in shareholding by chairman of the board
- Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
Later from InSilico Medicine Cayman TopCo
- Voluntary announcement InSilico Medicine nominates peripheral-restricted VAV1 molecular glue degrader for potential treatment of autoimmune diseases
- Voluntary announcement InSilico Medicine triggers a milestone payment in AI-driven R&D collaboration with servier for achieving early drug discovery milestone
Follow InSilico Medicine Cayman TopCo into a list and get an email when it puts out news.
Follow InSilico Medicine Cayman TopCo